Lanfear et al. (2005) demonstrated that Glu27 homozygosity of the ADRB2 rs1042714 polymorphism was a protective factor against all-cause mortality only in CAD patients who were treated with β-blockers, whereas they failed to demonstrate any protective effects in patients who were not treated with β-blockers. This evidence concerns the gene ADRB2 and coronary artery disorder.